News

Recent News

May 5, 2022

Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University

February 2, 2022

Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma

November 1, 2021

Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation

October 20, 2021

Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference

October 12, 2021

Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering’s Immuno-Oncology and Modular Vaccine Platform Candidates

October 6, 2021

Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego

October 1, 2021

Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering’s Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates

September 27, 2021

Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology 

September 23, 2021

Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform 

September 21, 2021

Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego

June 29, 2021

Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101

June 28, 2021

Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting

June 15, 2021

Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors

January 19, 2021

Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB Venture Market and Upcoming Presentation at the B. Riley Oncology Investor Conference

December 30, 2020

Mosaic ImmunoEngineering Inc. Announces Stock Symbol Change to “CPMV”

December 14, 2020

Mosaic ImmunoEngineering Inc. Provides an Overview of Development Plans for Advancing Its Lead Immuno-Oncology Product Candidate MI-O-101

December 1, 2020

Patriot Scientific Corporation Announces Name Change to "Mosaic ImmunoEngineering Inc.", Stock Symbol Change and Reverse Stock Split

August 31, 2020

Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases

August 24, 2020

Patriot Scientific Corporation and Mosaic ImmunoEngineering Inc. Enter into Definitive Merger Agreement